BR112018071705A2 - método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i) - Google Patents
método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i)Info
- Publication number
- BR112018071705A2 BR112018071705A2 BR112018071705-3A BR112018071705A BR112018071705A2 BR 112018071705 A2 BR112018071705 A2 BR 112018071705A2 BR 112018071705 A BR112018071705 A BR 112018071705A BR 112018071705 A2 BR112018071705 A2 BR 112018071705A2
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- compound
- nafld
- nash
- ash
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 abstract 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 abstract 1
- 229960005297 nalmefene Drugs 0.000 abstract 1
- 229960003086 naltrexone Drugs 0.000 abstract 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326435P | 2016-04-22 | 2016-04-22 | |
| USUS62/326,435 | 2016-04-22 | ||
| US201662395436P | 2016-09-16 | 2016-09-16 | |
| USUS62/395,436 | 2016-09-16 | ||
| PCT/US2017/028529 WO2017184819A1 (en) | 2016-04-22 | 2017-04-20 | Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071705A2 true BR112018071705A2 (pt) | 2019-02-19 |
Family
ID=58668969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071705-3A BR112018071705A2 (pt) | 2016-04-22 | 2017-04-20 | método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10045977B2 (enExample) |
| EP (1) | EP3445363A1 (enExample) |
| JP (1) | JP2019514872A (enExample) |
| KR (1) | KR20180129909A (enExample) |
| CN (2) | CN109069503A (enExample) |
| AU (1) | AU2017253228B2 (enExample) |
| BR (1) | BR112018071705A2 (enExample) |
| CA (1) | CA3021788C (enExample) |
| RU (1) | RU2717677C1 (enExample) |
| WO (1) | WO2017184819A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| US20190247373A1 (en) * | 2016-07-14 | 2019-08-15 | Children's Hospital Medical Center | Methods for treating fibrosis |
| SG11201903697WA (en) | 2016-11-04 | 2019-05-30 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| US12297457B2 (en) | 2017-10-10 | 2025-05-13 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| US12421500B2 (en) | 2018-07-26 | 2025-09-23 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| JP2021535753A (ja) | 2018-09-12 | 2021-12-23 | チルドレンズ ホスピタル メディカル センター | 造血幹細胞およびその派生体の生成のためのオルガノイド組成物 |
| WO2020160371A1 (en) | 2019-02-01 | 2020-08-06 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| CA3141814A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| CN114174494A (zh) | 2019-05-31 | 2022-03-11 | 儿童医院医学中心 | 产生和扩增造血干细胞的方法 |
| CA3236690A1 (en) | 2021-11-18 | 2023-05-25 | Ju Hee Kim | Sustained-release injectable composition containing naltrexone and method for preparing same |
| CN118234488A (zh) | 2021-11-18 | 2024-06-21 | 创技公司株式会社 | 包含难溶性药物的微粒的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086058A (en) * | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
| AU2003234621A1 (en) | 2002-05-17 | 2003-12-02 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US7923454B2 (en) * | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US8017622B2 (en) * | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US10363251B2 (en) * | 2009-07-16 | 2019-07-30 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| TR201002473A2 (tr) * | 2010-03-31 | 2011-09-21 | Mustafa Nevzat �La� Sanay�� A.�. | Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi. |
| CN102048733B (zh) | 2010-12-23 | 2011-12-28 | 武汉同源药业有限公司 | 盐酸纳美芬在制备治疗脂肪肝的药物中的用途 |
| MY180160A (en) * | 2013-04-22 | 2020-11-23 | Cadila Healthcare Ltd | A novel composition for nonalcoholic fatty liver disease (nafld) |
| EP3416619A2 (en) * | 2016-02-18 | 2018-12-26 | Immune Therapeutics, Inc. | Method for inducing a sustained immune response |
-
2017
- 2017-04-20 CN CN201780024846.0A patent/CN109069503A/zh active Pending
- 2017-04-20 EP EP17721252.9A patent/EP3445363A1/en not_active Ceased
- 2017-04-20 CA CA3021788A patent/CA3021788C/en active Active
- 2017-04-20 CN CN202311054107.XA patent/CN117137917A/zh active Pending
- 2017-04-20 WO PCT/US2017/028529 patent/WO2017184819A1/en not_active Ceased
- 2017-04-20 RU RU2018136387A patent/RU2717677C1/ru active
- 2017-04-20 AU AU2017253228A patent/AU2017253228B2/en active Active
- 2017-04-20 JP JP2018554716A patent/JP2019514872A/ja active Pending
- 2017-04-20 KR KR1020187031996A patent/KR20180129909A/ko not_active Ceased
- 2017-04-20 US US15/492,198 patent/US10045977B2/en active Active
- 2017-04-20 BR BR112018071705-3A patent/BR112018071705A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017253228B2 (en) | 2020-04-09 |
| CN117137917A (zh) | 2023-12-01 |
| US20170304294A1 (en) | 2017-10-26 |
| RU2717677C1 (ru) | 2020-03-25 |
| CA3021788A1 (en) | 2017-10-26 |
| EP3445363A1 (en) | 2019-02-27 |
| AU2017253228A1 (en) | 2018-09-27 |
| AU2017253228A8 (en) | 2019-01-17 |
| KR20180129909A (ko) | 2018-12-05 |
| US10045977B2 (en) | 2018-08-14 |
| CA3021788C (en) | 2021-08-03 |
| WO2017184819A1 (en) | 2017-10-26 |
| CN109069503A (zh) | 2018-12-21 |
| JP2019514872A (ja) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263947B (en) | Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof | |
| NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
| NZ733125A (en) | Isoquinoline compounds for the treatment of hiv | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| EP4306168A3 (en) | Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| MY197673A (en) | Combination comprising ep4 antagonist and immune checkpoint inhibitor | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| BR112019020421A8 (pt) | Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| MX2019015524A (es) | Composiciones inmunogenicas. | |
| TN2015000542A1 (en) | Novel compounds for the treatment of cancer | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| PH12017501122A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| PH12015502746A1 (en) | Prodrug derivatives of substituted triazolopyridines | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| BR112016008704A8 (pt) | derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |